From Family Experience to Innovation: Australian breakthrough offers fast, science-backed relief for period pain
Announcement posted by EVE Health Group 14 Oct 2025
Media Release- October 2025
In a major step forward for women's health innovation, EVE Health Group has launched Dyspro, a prescription-only multi-cannabinoid-based gummy clinically formulated to deliver rapid relief from menstrual pain in under 20 minutes.
Developed and manufactured in Australia to Good Manufacturing Practice (GMP) standards, Dyspro uses EVE's proprietary technology to enhance bioavailability and accelerate onset of action, offering women a natural, non-hormonal, fast-acting alternative to conventional painkillers and hormonal therapies.
The first Australian prescriptions have been issued under the Therapeutic Goods Administration's Special Access Scheme and Authorised Prescriber pathways.
For EVE Health Group CEO Damian Wood, the product is personal.
"Dyspro was born out of my family's experience. Seeing the pain my wife and 12-year-old daughter struggled with period pain every month made it clear that something had to change," said Wood. "It was important that we created a product that worked fast, yet was gentle, and backed by science. This isn't just innovation, it's about putting people, not just symptoms, at the centre of what we create."
Dysmenorrhoea (period pain) affects over 70% of Australian women of reproductive age, with national economic impacts estimated at $14.2 billion annually. Despite this, effective non-hormonal options remain limited. Dyspro was developed through two years of R&D, clinical input from Australian healthcare professionals, and laboratory validation of its advanced formulation.
With recent new capital funding, EVE Health Group is continuing to expand prescriber education and telehealth access through partners such as TeleDocs Clinic, alongside plans for international market expansion in 2026. The product's launch is accompanied by "Reclaim My Cycle", a dedicated online platform that connects women, clinicians, and advocates focused on improving menstrual wellbeing.
"Women's pain has been overlooked for too long," Wood added. "We're building a future where it's taken seriously, where fast relief and real women-centred solutions go hand in hand."
About EVE Health Group
EVE Health Group is an Australian ASX listed health innovation company dedicated to improving women's health through innovative pharmaceuticals and nutraceuticals through its proprietary solubility and delivery systems. Its mission is to combine evidence-based science with human-centred design to create medical management to help restore comfort, dignity, and control.
Media Enquiries:
EVE Health Group
Rebecca Bak | Marketing Manager
e: rebeccab@evehealthgroup.com.au
References
RACGP. Prevalence and severity of dysmenorrhoea, and management options. Australian Family Physician. 2016.
Jean Hailes for Women's Health. Pelvic Pain in Australian Women: National Women's Health Survey 2023 - Key Findings. Jean Hailes. 2023.
The Medical Journal of Australia. Menstrual pain in Australian adolescent girls and its impact on regular activities. MJA. 2024;220(9).
ABC News. The economic cost of painful menstrual symptoms. ABC. 2025.
Women's Agenda. Untreated painful periods can cost economy up to $14.2 billion per year. Women's Agenda. 2025.
The Medical Journal of Australia. Ending the neglect of menstrual pain in adolescents is key to improving outcomes for people with period pain. MJA. 2024.